IP Library Granted Patent US 8,414,909
Granted Patent B2
US 8,414,909 · App. 11/942,452 · Granted Apr 9, 2013

Drug releasing coatings for medical devices

Inventor: Lixiao Wang (Medina, MN)
Assignee: Lutonix, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,414,909
App. No.
11/942,452
Granted
Apr 9, 2013
Kind
B2
Abstract

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.

Claims (27)

1. A balloon catheter for delivering a therapeutic agent to a target site of a blood vessel, the balloon catheter comprising:

an inflatable polyamide balloon; and

a coating layer that adheres to an exterior surface of the inflatable polyamide balloon,

wherein:

the coating layer comprises a hydrophobic therapeutic agent and at least one water-soluble additive;

the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof;

the at least one water-soluble additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates; and

the coating layer does not include an iodine covalent bonded contrast agent.

2. The balloon catheter of claim 1 , wherein the PEG fatty ester is selected from the group consisting of PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan stearates, PEG sorbitan monolaurates, and PEG sorbitan monooleates.

3. The balloon catheter of claim 1 , wherein the at least one water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate.

4. The balloon catheter of claim 1 , wherein the at least one water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate.

5. The balloon catheter of claim 4 , wherein the coating layer consists essentially of the therapeutic agent and the at least one water-soluble additive.

6. The balloon catheter of claim 1 , wherein the concentration of the therapeutic agent in the coating layer is from 1 μg/mm 2 to 20 μg/mm 2 .

7. The balloon catheter of claim 1 , wherein the concentration of the therapeutic agent in the coating layer is from 2 μg/mm 2 to 6 μg/mm 2 .

8. The balloon catheter of claim 1 , wherein the concentration of the at least one water-soluble additive in the coating layer is from 1 μg/mm 2 to 10 μg/mm 2 .

9. The balloon catheter of claim 1 , wherein the ratio by weight of the at least one water-soluble additive to the therapeutic agent in the coating layer is from about 0.1 to 5.

10. The balloon catheter of claim 1 , wherein the ratio by weight of the at least one water-soluble additive to the therapeutic agent in the coating layer is from about 0.5 to 2.

11. The balloon catheter of claim 1 , wherein the ratio by weight of the at least one water-soluble additive to the therapeutic agent in the coating layer is from about 0.8 to 1.2.

12. The balloon catheter of claim 1 , wherein the balloon catheter is a perfusion balloon catheter, a cutting balloon catheter, or a scoring balloon catheter.

13. The balloon catheter of claim 1 , further comprising a top layer overlying the surface of the coating layer to prevent loss of the hydrophobic therapeutic agent during transit of the balloon catheter through the blood vessel to the target site.

14. The balloon catheter of claim 1 , further comprising a dimethylsulfoxide solvent layer overlying the surface of the coating layer.

15. The balloon catheter according to claim 1 , wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel and rapamycin.

16. The balloon catheter of claim 1 , wherein the hydrophobic therapeutic agent is paclitaxel.

17. The balloon catheter of claim 1 , further comprising a bare-metal stent crimped on the balloon.

18. The balloon catheter of claim 1 , wherein the coating layer further comprises a second hydrophobic therapeutic agent selected from the group consisting of beta-lapachone and a biologically active vitamin D.

19. The balloon catheter of claim 1 , further comprising an adherent layer between the exterior surface of the inflatable polyamide balloon and the coating layer.

20. The balloon catheter of claim 1 , further comprising a top layer overlying the coating layer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2008
From: WANG, LIXIAO
To: LUTONIX, INC.
Reel/Frame 020439/0151 →
Continuity (9)
Provisional Application 60860084 · Nov 20, 2006
Provisional Application 60880742 · Jan 17, 2007
Provisional Application 60897427 · Jan 25, 2007
Provisional Application 60903529 · Feb 26, 2007
Provisional Application 60926850 · Apr 30, 2007
Provisional Application 60904473 · Mar 2, 2007
Provisional Application 60981380 · Oct 19, 2007
Provisional Application 60981384 · Oct 19, 2007
Related Publication 20080118544A1 · May 22, 2008